Literature DB >> 22748003

Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011.

M Unemo1, D Golparian, M Potočnik, S Jeverica.   

Abstract

We describe the second case in Europe of verified treatment failure of pharyngeal gonorrhoea, caused by an internationally occurring multidrug-resistant gonococcal clone, with recommended first-line ceftriaxone 250 mg in Slovenia. This is of grave concern since ceftriaxone is last remaining option for empirical treatment. Increased awareness of ceftriaxone failures, more frequent test-of-cure, strict adherence to regularly updated treatment guidelines, and thorough verification/falsification of suspected treatment failures are essential globally. New effective treatment options are imperative.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22748003

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  45 in total

1.  Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of Neisseria gonorrhoeae in Ireland, 2014-2016: focus on extended-spectrum cephalosporins and azithromycin.

Authors:  L Ryan; D Golparian; N Fennelly; L Rose; P Walsh; B Lawlor; M Mac Aogáin; M Unemo; B Crowley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-07       Impact factor: 3.267

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 3.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Prevalence of gonococcal conjunctivitis in adults and neonates.

Authors:  L McAnena; S J Knowles; A Curry; L Cassidy
Journal:  Eye (Lond)       Date:  2015-04-24       Impact factor: 3.775

5.  Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.

Authors:  Magnus Unemo; Daniel Golparian; Vegard Skogen; Anne Olaug Olsen; Harald Moi; Gaute Syversen; Stig Ove Hjelmevoll
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

6.  Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).

Authors:  Xiao-Hong Su; Bao-Xi Wang; Wen-Jing Le; Yu-Rong Liu; Chuan Wan; Sai Li; Richard A Alm; John P Mueller; Peter A Rice
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

7.  Insights in public health: The hidden epidemic: sexually transmitted diseases in 2014.

Authors:  Alan R Katz
Journal:  Hawaii J Med Public Health       Date:  2014-08

8.  High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Authors:  Susanne Jacobsson; Daniel Golparian; Richard A Alm; Michael Huband; John Mueller; Jorgen Skov Jensen; Makoto Ohnishi; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

9.  Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone with decreased susceptibility and resistance to extended-spectrum cephalosporins.

Authors:  David Hess; Abel Wu; Daniel Golparian; Sarah Esmaili; Will Pandori; Emilee Sena; Jeffrey D Klausner; Pennan Barry; Magnus Unemo; Mark Pandori
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  Description of an unusual Neisseria meningitidis isolate containing and expressing Neisseria gonorrhoeae-Specific 16S rRNA gene sequences.

Authors:  Marion Walcher; Rhonda Skvoretz; Megan Montgomery-Fullerton; Vivian Jonas; Steve Brentano
Journal:  J Clin Microbiol       Date:  2013-07-17       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.